尿路がんの世界市場レポート 2024年

尿路がんの市場規模は近年急激に拡大しています。2023年の26億5,000万米ドルから2024年には32億1,000万米ドルに、CAGR21.1％で成長します。実績期間の成長は、診断、医薬品開発、意識向上、早期発見、精密医療における進歩に起因しています。

尿路がんの市場規模は今後数年で急成長が見込まれます。2028年にはCAGR19.3％で64億9,000万米ドルに成長します。予測期間の成長は、免疫療法の進歩、遠隔医療と遠隔モニタリング、バイオマーカー調査、補助療法に起因しています。予測期間の主な動向には、世界の協力体制、緩和ケアの進歩、包括的サバイバーシッププログラム、患者中心のケアなどがあります。

膀胱がんの有病率の増加が予想され、尿路がん市場の成長を後押しします。膀胱がんは、体外に排出される前の尿を貯留する重要な臓器である膀胱の組織にがん細胞が発生することが特徴です。この有病率の増加は、診断ツール、スクリーニング方法、尿路がんに罹患した人のための治療オプションに対する需要の高まりにつながっています。例えば、2023年1月、米国を拠点とするがん啓発団体である米国がん協会（American Cancer Society Inc.）の報告書によると、米国における泌尿器系がんの推定症例数は2023年には168,560例となり、2022年の164,190例から2.66％増加することが明らかになった。さらに、膀胱がん患者は2021年には83,730人に増加し、2020年の81,400人から2.8％増加しました。したがって、膀胱がんの有病率の増加は、尿路がん市場の成長の重要な促進要因になると予測されます。

尿路感染症の有病率の増加は、今後の尿路がん市場の拡大を牽引すると予測されています。尿路感染症は、腎臓、膀胱、尿管、尿道など泌尿器系のさまざまな部位に影響を及ぼす細菌感染症です。感染の拡大を防ぐためには、効果的な治療と管理が必要であり、これは複数の方法でがんにつながる可能性があります。例えば、米国を拠点とする公衆衛生研究機関である国立衛生研究所（National Institute of Health）は2023年1月の時点で、尿路感染症は米国で患者が救急外来を受診する理由として7番目に多く、年間100万人以上が受診していると報告しています。これらの症例のうち22％（22万件）が複雑性尿路結石と分類され、毎年約10万人の患者が入院しています。したがって、尿路感染症の有病率の上昇が尿路がん市場の成長の原動力となっています。

2023年の尿路がん市場で最大の地域は北米でした。尿路がんレポートの対象地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の尿路がん市場、がんタイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 膀胱がん
• 尿道がん
• 尿管がんと腎盂がん
• 世界の尿路がん市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 化学療法
• 膀胱内療法
• 放射線治療
• 手術
• 世界の尿路がん市場、診断技術別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 膀胱鏡検査
• 経尿道的腫瘍切除術
• 画像検査
• 尿分析
• その他の診断手法
• 世界の尿路がん市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 小売薬局
• オンライン薬局

第7章 地域および国の分析

• 世界の尿路がん市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
• 世界の尿路がん市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 尿路がん市場の競合情勢
• 尿路がん市場企業プロファイル
  • Pfizer Inc.
  • Johnson &Johnson
  • F. Hoffmann-La Roche Ltd
  • Merck KGaA
  • Bayer AG

第31章 その他の主要および革新的な企業

• Novartis AG
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline PLC (GSK)
• Eli Lilly and Company
• Amgen Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Boehringer Ingelheim GmbH
• Incyte Corporation
• Shionogi & Co. Ltd.
• Kyowa Hakko Kirin Co. Ltd
• Endo International PLC
• Seagen Inc.
• Exelixis Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

“Urinary Tract Cancer Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urinary tract cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urinary tract cancer? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The urinary tract cancer market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Cancer Type: Bladder Cancer; Urethral Cancer; Ureteric And Renal Pelvic Cancer
• 2) By Treatment: Chemotherapy; Intravesical Therapy; Radiation Therapy; Surgery
• 3) By Diagnostic Techniques: Cystoscopy; Transurethral Resection Of The Tumor; Imaging Tests; Urine Analyses; Other Diagnostic Techniques
• 4) By Distribution Channel: Retail Pharmacy; Online Pharmacy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd; Merck KGaA; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Urinary tract cancer encompasses malignancies that can develop in the kidneys, bladder, ureters, or urethra, often leading to symptoms like hematuria (blood in the urine) and pain. Taking preventive measures, such as quitting smoking, avoiding exposure to harmful substances, and promptly addressing urinary tract infections, can help reduce the risk of developing urinary tract cancer.

The primary types of urinary tract cancer include bladder cancer, urethral cancer, ureteric cancer, and renal pelvic cancer. Bladder cancer is characterized by abnormal cell growth in the lining of the bladder, directly affecting the urinary system, as the bladder plays a crucial role in this system. Treatments for bladder cancer typically involve approaches like radical cystectomy, radiation therapy, targeted therapy, chemotherapy, intravenous therapy, radiation therapy, and surgery. Diagnosis is typically conducted through methods such as cystoscopy, transurethral resection of the tumor, imaging tests, urine analyses, and various other techniques. Products for both treatment and diagnosis are distributed through channels such as retail pharmacies and online pharmacies.

The urinary tract cancer market research report is one of a series of new reports from The Business Research Company that provides urinary tract cancer market statistics, including urinary tract cancer industry global market size, regional shares, competitors with a urinary tract cancer market share, detailed urinary tract cancer market segments, market trends and opportunities and any further data you may need to thrive in the urinary tract cancer industry. This urinary tract cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urinary tract cancer market size has grown exponentially in recent years. It will grow from $2.65 billion in 2023 to $3.21 billion in 2024 at a compound annual growth rate (CAGR) of 21.1%. The growth in the historic period can be attributed to advancements in diagnostics, pharmaceutical developments, awareness and early detection, precision medicine.

The urinary tract cancer market size is expected to see rapid growth in the next few years. It will grow to $6.49 billion in 2028 at a compound annual growth rate (CAGR) of 19.3%. The growth in the forecast period can be attributed to immunotherapy advancements, telemedicine and remote monitoring, biomarker research, adjuvant therapies. Major trends in the forecast period include global collaboration, advances in palliative care, comprehensive survivorship programs, patient-centric care.

The anticipated rise in the prevalence of bladder cancer is set to fuel the growth of the urinary tract cancer market. Bladder cancer is characterized by the development of cancerous cells in the tissues of the urinary bladder, a crucial organ responsible for storing urine before its elimination from the body. This increased prevalence is leading to a greater demand for diagnostic tools, screening methods, and treatment options for individuals affected by urinary tract cancer. For example, in January 2023, a report by the American Cancer Society Inc., a U.S.-based cancer awareness organization, revealed an estimated increase in urinary system cancer cases to 168,560 in 2023, representing a 2.66% rise from 164,190 in 2022 in the United States. Additionally, cases of bladder cancer increased to 83,730 in 2021, a 2.8% increase from 81,400 in 2020. Hence, the growing prevalence of bladder cancer is expected to be a significant driver of the urinary tract cancer market's growth.

The increasing prevalence of urinary tract infections is anticipated to drive the expansion of the urinary tract cancer market in the future. Urinary tract infections result from bacterial infections that can affect various parts of the urinary system, including the kidneys, bladder, ureters, and urethra. Effective treatment and management are required to prevent the spread of infection, which can potentially lead to cancer in multiple ways. For instance, as of January 2023, the National Institute of Health, a U.S.-based public health research agency, reported that urinary tract infections constituted the seventh most common reason for patients to visit an emergency department in the USA, with over 1 million visits annually. Of these cases, 22% (220,000) were classified as complicated UTIs, and approximately 100,000 patients were admitted each year. Hence, the rising prevalence of urinary tract infections is a driving force behind the growth of the urinary tract cancer market.

The urinary tract cancer market faces potential constraints due to side effects associated with chemotherapy during the forecast period. Patients may be hesitant to undergo chemotherapy treatment due to the possible side effects, leading to reduced demand for chemotherapy drugs and related products used in the treatment of urinary tract cancer. For instance, in April 2023, a medical science journal publication, Cureus, reported that the top three adverse effects of chemotherapy, as cited by 77 respondents, included diarrhea (49.4%), loss of appetite (71.4%), and fatigue (87%). Around 66.7% of participants experienced six or more side effects. Therefore, the side effects linked to chemotherapy are impacting the growth of the urinary tract cancer market.

Leading companies operating in the urinary tract cancer market are increasingly focusing on advancing treatment methods to provide more effective and personalized solutions, gaining a competitive edge in the market. These advancements in urinary tract cancer treatment emphasize precise interventions, harnessing the body's immune system, improving surgical techniques, and tailoring treatments to meet the specific needs of individual patients. For example, in October 2022, UC San Diego Health, a U.S.-based healthcare system, introduced an advanced treatment for patients with low-grade upper tract urothelial cancer (LG-UTUC), a relatively uncommon subtype of urinary system cancer. This innovative treatment offers an alternative approach to the traditional complete kidney removal method, potentially sparing patients from the need for future dialysis or kidney transplants. The therapy involves the administration of Jelmyto, a drug containing mitomycin, a well-known chemotherapy agent, combined with a sterile hydrogel, delivered through guided injections that precisely target the tumor within the urinary system.

In July 2021, Pharmavite, a U.S.-based dietary supplement company, acquired Uqora for an undisclosed sum, bolstering its offerings in women's health. Uqora, a U.S.-based natural supplement company, specializes in developing supplements and reactive solutions designed to reduce the risk of urinary tract infections (UTIs).

Major players in the urinary tract cancer market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck KGaA, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC (GSK), Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Eisai Co. Ltd., Boehringer Ingelheim GmbH, Incyte Corporation, Shionogi & Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Endo International PLC, Seagen Inc., Exelixis Inc., Ferring Pharmaceuticals, Bavarian Nordic, EUSA Pharma, UroGen Pharma Inc., Mersana Therapeutics, Protara Therapeutics Inc., Spectrum Pharmaceuticals, IDL Biotech AB, AroCell AB, ImmunityBio Inc .

North America was the largest region in the urinary tract cancer market in 2023. The regions covered in urinary tract cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the urinary tract cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary tract cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgery and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The urinary tract cancer market also includes sales of urinary catheters, cystoscopes, imaging equipment, urine cytology kits, pain relief medications and physical therapy devices which are used in providing diagnostic services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Urinary Tract Cancer Market Characteristics

3. Urinary Tract Cancer Market Trends And Strategies

4. Urinary Tract Cancer Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Urinary Tract Cancer Market Size and Growth

• 5.1. Global Urinary Tract Cancer Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Urinary Tract Cancer Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Urinary Tract Cancer Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Urinary Tract Cancer Market Segmentation

• 6.1. Global Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Bladder Cancer
• Urethral Cancer
• Ureteric And Renal Pelvic Cancer
• 6.2. Global Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Chemotherapy
• Intravesical Therapy
• Radiation Therapy
• Surgery
• 6.3. Global Urinary Tract Cancer Market, Segmentation By Diagnostic Techniques, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cystoscopy
• Transurethral Resection Of The Tumor
• Imaging Tests
• Urine Analyses
• Other Diagnostic Techniques
• 6.4. Global Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Retail Pharmacy
• Online Pharmacy

7. Urinary Tract Cancer Market Regional And Country Analysis

• 7.1. Global Urinary Tract Cancer Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Urinary Tract Cancer Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Urinary Tract Cancer Market

• 8.1. Asia-Pacific Urinary Tract Cancer Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Urinary Tract Cancer Market

• 9.1. China Urinary Tract Cancer Market Overview
• 9.2. China Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Urinary Tract Cancer Market

• 10.1. India Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Urinary Tract Cancer Market

• 11.1. Japan Urinary Tract Cancer Market Overview
• 11.2. Japan Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Urinary Tract Cancer Market

• 12.1. Australia Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Urinary Tract Cancer Market

• 13.1. Indonesia Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Urinary Tract Cancer Market

• 14.1. South Korea Urinary Tract Cancer Market Overview
• 14.2. South Korea Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Urinary Tract Cancer Market

• 15.1. Western Europe Urinary Tract Cancer Market Overview
• 15.2. Western Europe Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Urinary Tract Cancer Market

• 16.1. UK Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Urinary Tract Cancer Market

• 17.1. Germany Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Urinary Tract Cancer Market

• 18.1. France Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Urinary Tract Cancer Market

• 19.1. Italy Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Urinary Tract Cancer Market

• 20.1. Spain Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Urinary Tract Cancer Market

• 21.1. Eastern Europe Urinary Tract Cancer Market Overview
• 21.2. Eastern Europe Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Urinary Tract Cancer Market

• 22.1. Russia Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Urinary Tract Cancer Market

• 23.1. North America Urinary Tract Cancer Market Overview
• 23.2. North America Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Urinary Tract Cancer Market

• 24.1. USA Urinary Tract Cancer Market Overview
• 24.2. USA Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Urinary Tract Cancer Market

• 25.1. Canada Urinary Tract Cancer Market Overview
• 25.2. Canada Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Urinary Tract Cancer Market

• 26.1. South America Urinary Tract Cancer Market Overview
• 26.2. South America Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Urinary Tract Cancer Market

• 27.1. Brazil Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Urinary Tract Cancer Market

• 28.1. Middle East Urinary Tract Cancer Market Overview
• 28.2. Middle East Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Urinary Tract Cancer Market

• 29.1. Africa Urinary Tract Cancer Market Overview
• 29.2. Africa Urinary Tract Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Urinary Tract Cancer Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Urinary Tract Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Urinary Tract Cancer Market Competitive Landscape And Company Profiles

• 30.1. Urinary Tract Cancer Market Competitive Landscape
• 30.2. Urinary Tract Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Johnson & Johnson
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche Ltd
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Merck KGaA
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bayer AG
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Urinary Tract Cancer Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. GlaxoSmithKline PLC (GSK)
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Astellas Pharma Inc.
• 31.8. Eisai Co. Ltd.
• 31.9. Boehringer Ingelheim GmbH
• 31.10. Incyte Corporation
• 31.11. Shionogi & Co. Ltd.
• 31.12. Kyowa Hakko Kirin Co. Ltd
• 31.13. Endo International PLC
• 31.14. Seagen Inc.
• 31.15. Exelixis Inc.

32. Global Urinary Tract Cancer Market Competitive Benchmarking

33. Global Urinary Tract Cancer Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Urinary Tract Cancer Market

35. Urinary Tract Cancer Market Future Outlook and Potential Analysis

• 35.1 Urinary Tract Cancer Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Urinary Tract Cancer Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Urinary Tract Cancer Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer